Your browser doesn't support javascript.
loading
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser, Stephen L; Kappos, Ludwig; Bar-Or, Amit; Wiendl, Heinz; Paling, David; Williams, Mitzi; Gold, Ralf; Chan, Andrew; Milo, Ron; Das Gupta, Ayan; Karlsson, Goeril; Sullivan, Roseanne; Graham, Gordon; Merschhemke, Martin; Häring, Dieter A; Vermersch, Patrick.
Afiliação
  • Hauser SL; UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. Stephen.Hauser@ucsf.edu.
  • Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, and Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital of Basel, University of Basel, Basel, Switzerland.
  • Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Wiendl H; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
  • Paling D; Sheffield Institute of Translational Neuroscience, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK.
  • Williams M; Joi Life Wellness Multiple Sclerosis Neurology Center, Atlanta, GA, USA.
  • Gold R; Department of Neurology, St Josef-Hospital/Ruhr-University Bochum, Bochum, Germany.
  • Chan A; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Milo R; Department of Neurology, Barzilai Medical Center, Ashkelon/Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Das Gupta A; Novartis Pharma AG, Basel, Switzerland.
  • Karlsson G; Novartis Pharma AG, Basel, Switzerland.
  • Sullivan R; Novartis Pharma AG, Basel, Switzerland.
  • Graham G; Novartis Pharma AG, Basel, Switzerland.
  • Merschhemke M; Novartis Pharma AG, Basel, Switzerland.
  • Häring DA; Novartis Pharma AG, Basel, Switzerland.
  • Vermersch P; Univ. Lille, INSERM U1172 LilNCog, CHU Lille, FHU Precise, 59000, Lille, France.
Neurol Ther ; 12(5): 1491-1515, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37450172
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Neurol Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Neurol Ther Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos